TABLE 2.
Patient Characteristics and Results of [89Zr]Zr-DFO-SC16.56 DLL3 immunoPET-CT Imaging
| Patient No. | Tumor Type | DLL3 IHC H-Score (biopsy location) | No. of Previous Lines of Systemic Therapy for Advanced Disease | Most Recent Systemic Therapy Before DLL3 ImmunoPET CT | DLL3 ImmunoPET-CT–Avid | SUVmax of Highest DLL3-Avid Lesion (location) | Blood Pool Uptake, SUVmean | Tumor/Liver Ratio, SUVmax/SUVmean | No. (%) of Tumor Lesions DLL3 ImmunoPET-CT–Positive | Among DLL3 immunoPET-CT–Positive Tumor Lesions, 68Ga-DOTATATE–Positive (PanNET only, %) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pancreatic NEC | 270 (liver) | 2 | CAPOX | Yes | 36.7 (liver) | 1.6 | 5.7 | 20/21 (95) | NA |
| 2 | Gallbladder NEC | 120 (supraclavicular lymph node) | 4 | Carboplatin + etoposide | Yes | 32.4 (liver) | 7.9 | 4.8 | 16/16 (100) | NA |
| 3 | G3 PanNET | 90 (liver) | 4 | Capecitabine + temozolomide | No | 7.4 (abdominal lymph node) | 7.9 | 1.1 | 0/22 (0) | NA |
| 4 | G3 PanNET | 120 (liver) | 2 | Capecitabine + temozolomide | Yes | 14.4 (liver) | 4.8 | 3.1 | 1/10 (10) | 0 |
| 5 | G3 PanNET | 90 (pancreatic primary) | 3 | 177Lu-DOTATATE | Yes | 27.5 (liver) | 3.9 | 5.2 | 38/38 (100) | 100 |
| 6 | G3 PanNET | 30 (liver) | 3 | CAPOX | Yes | 15.0 (liver) | 5.5 | 2.7 | 4/8 (50) | 100 |
Abbreviations: CAPOX, capecitabine and oxaliplatin; CT, computed tomography; DLL3, delta-like ligand 3; G3, grade 3; IHC, immunohistochemistry; NA, not applicable; NEC, neuroendocrine carcinoma; PanNET, pancreatic neuroendocrine tumor; PET, positron emission tomography; SUV, standard uptake value.